Clinical Trial Update: Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial update reports that co-administration of cabergoline and gliclazide improves glycemic parameters and lipid profile in patients with type 2 diabe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• CABERGOLINE (CABERGOLINE)
• Gliclazide (gliclazide)

Snippet

Sponsor: Sherief Abd-Elsalam | Conditions: Diabetes | Phase 3 | Status: UNKNOWN